Исследование ассоциации полиморфного локуса rs13181 гена ERCC2 с риском развития рака яичников

На основании вышеизложенного целью данной работы стало изучение полиморфного локуса rs13181 гена репарации ДНК ERCC2 и его ассоциации с риском заболевания раком яичников у женщин из Республики Башкортостан.
Для достижения поставленной цели были сформулированы следующие задачи исследования:
1. Провести анализ распределения частот аллелей и генотипов полиморфного локуса rs13181 гена ERCC2 у больных РЯ и индивидов контрольной группы.
2. Провести анализ распределения частот аллелей и генотипов полиморфного локуса rs13181 гена ERCC2 у индивидов контрольной группы.
3. Провести анализ ассоциации гена ERCC2 с риском развития рака яичников у женщин из Республики Башкортостан.

ВВЕДЕНИЕ 3
1. Обзор литературы 5
1.1. Эпидемиология рака яичников 8
1.2. Факторы риска рака яичников 9
1.3. Классификация рака яичников 16
1.4. Гены кандидаты рака яичников 20
2. Материалы и методы исследования 28
2.1. Материалы исследования 28
2.2. Методы исследования 30
2.2.1. Выделение геномной ДНК 30
2.2.2. Полимеразная цепная реакция синтеза ДНК 33
2.2.3. Полиморфизм длин рестрикционных фрагментов (ПДРФ – анализ) 36
2.2.4. Метод электрофореза в полиакриламидном (ПААГ) геле 37
3. Результаты и обсуждение 39
3.1. Статистические методы анализа данных 39
3.2. Анализ ассоциации полиморфного локуса rs13181 гена ERCC2 с риском развития рака яичников 40
ЗАКЛЮЧЕНИЕ 48
ВЫВОДЫ 50
СПИСОК ЛИТЕРАТУРЫ 51

Дата изготовления: май 2022 года.
Учебное заведение: Башкирский Государственный Университет.
Оригинальность по Антиплагиат.ру составила 60%.
Работа была успешно сдана - заказчик претензий не имел.

1) Жорданиа К. И., Калиничева Е. В., Моисеев А. А. Рак яичников: эпидемиология, морфология и гистогенез //Онкогинекология. – 2017 – №. 3 – С. 26-32.
2) Каприн А.Д., Старинский В.В., Шахзадова А.О. Злокачественные новообразования в России в 2020 году (заболеваемость и смертность) – М.: МНИОИ им. П.А. Герцена − филиал ФГБУ «НМИЦ радиологии» Минздрава России, − 2021 − илл. − 252 с.
3) Alberg AJ, Moorman PG, Crankshaw S, et al. Socioeconomic status in relation to the risk of Ovarian cancer in African-American Women: a population-based case-control study. Am J Epidemiol. 2017 - 184.
4) Alsop K, Fereday S, Meldrum C, et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J Clin Oncol 2018;30:2654-2663.
5) Andrews L, Mutch DG. Hereditary ovarian cancer and risk reduction. Best Pract Res Clin Obstet Gynaecol. 2017;41:31–48. doi:10.1016/j.bpobgyn.2016.10.017.
6) Arora N, Talhouk A, McAlpine JN, Law MR, Hanley GE. Longterm mortality among women with epithelial ovarian cancer: a population-based study in British Columbia, Canada. BMC Cancer. 2018 – 18.
7) Bandera EV, Lee VS, Qin B, Rodriguez-Rodriguez L, Powell CB, Kushi LH. Impact of body mass index on ovarian cancer survival varies by stage. Br J Cancer. 2017;117(2):282–289.
8) Beehler GP, Sekhon M, Baker JA, et al. Risk of ovarian cancer associated with BMI varies by menopausal status. J Nutr. 2017;136(11):2881–2886.
9) Bernard-Gallon, D., Bosviel, R., Delort, L. et al. DNA repair gene ERCC2 polymorphisms and associations with breast and ovarian cancer risk. Mol Cancer 7, 36 (2017).
10) Borley J, Wilhelm-Benartzi C, et al. Radiological predictors of cytoreductive outcomes in patients withadvanced ovarian cancer. BJOG. 2015;122(6):843-9.
11) Chiang AJ, Chang C, Huang C-H, Huang W-C, Kan Y-Y CJ. Risk factors in progression from endometriosis to ovarian cancer: a cohort study based on medical insurance data. J Gynecol Oncol. 2018;29:3.
12) Cibula D, Widschwendter M, Zikan M, Dusek L. Underlying mechanisms of ovarian cancer risk reduction after tubal ligation. Acta Obstet Gynecol Scand. 2017;90(6):559–563.
13) Coin,F., Bergmann,E., Tremeau-Bravard,A. and Egly,J.M. Mutations in XPB and XPD helicases found in xeroderma pigmentosum patients impair the transcription function of TFIIH. EMBO J., 18, 1357–1366.
14) Crum CP, Drapkin R, Kindelberger D, et al. Lessons from BRCA: the tubal fimbria emerges as an origin for pelvic serous cancer. Clin Med Res 2017;5:35-44
15) Falconer H, Yin L, Gronberg H, Altman D. Ovarian cancer risk after salpingectomy: a nationwide population-based study. J Natl Cancer Inst. 2017;107:2.
16) Gillet L.C., Scharer O.D. Molecular mechanisms of mammalian global genome nucleotide excision repair. // Chem. Rev. — 2017 — № 106. — P. 253—276
17) Goodman MT, Wu AH, Tung KH, et al. Association of dairy products, lactose, and calcium with the risk of ovarian cancer. Am J Epidemiol. 2019;156(2):148–157.
18) Gram IT, Braaten T, Adami HO, Lund E, Weiderpass E. Cigarette smoking and risk of borderline and invasive epithelial ovarian cancer. Int J Cancer. 2018;122(3):647–652.
19) Helder-Woolderink J, Blok E, Vasen H, Hollema H, Mourits M, De Bock G. Ovarian cancer in Lynch syndrome; a systematic review. Eur J Cancer. 2017;55:65–73. doi:10.1016/j.ejca.2015.12.005.
20) Helleday T, Petermann E, Lundin C, et al. DNA repair pathways as targets for cancer therapy. Nat Rev Cancer 2017;8(3):193-204.
21) Itin,P.H., Sarasin,A. and Pittelkow,M.R. (2001) Trichothiodystrophy: updateon the sulfur-deficient brittle hair syndromes. J. Am. Acad. Dermatol., 44, 891–920.
22) Jia D, Nagaoka Y, Katsumata M, Orsulic S. Inflammation is a key contributor to ovarian cancer cell seeding. Sci Rep. 2018;8 (1):12394.
23) Jordan SJ, Webb PM, Green AC. Height, age at menarche, and risk of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2017(8):2045–2048.
24) Kazerouni N, Greene MH, Lacey JV Jr., Mink PJ, Schairer C. Family history of breast cancer as a risk factor for ovarian cancer in a prospective study. Cancer. 2018;107(5):1075–1083.
25) Kraemer,K.H., Levy,D.D., Parris,C.N., Gozukara,E.M., Moriwaki,S., Adelberg,S. and Seidman,M.M. Xeroderma pigmentosum and related disorders: examining the linkage between defective DNA repair and cancer. J. Invest. Dermatol., 103, S96–S101.
26) Kuper H, Titus-Ernstoff L, Harlow BL, Cramer DW. Population based study of coffee, alcohol and tobacco use and risk of ovarian cancer. Int J Cancer. 2000;88(2):313–318.
27) Ledermann JA, Raja FA, et al. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Onco. 2018;24(Suppl 6):vi24-vi32.
28) Leitzmann MF, Koebnick C, Danforth KN, et al. Body mass index and risk of ovarian cancer. Cancer. 2017;115(4):812–822.
29) Li, J., Pan, L., Qin, X. et al. Association between ERCC2 rs13181 polymorphism and ovarian cancer risk: an updated meta-analysis with 4024 subjects. Arch Gynecol Obstet 296, 551–558 (2017).
30) Lunn,R.M., Helzlsouer,K.J., Parshad,R., Umbach,D.M., Harris,E.L., Sanford,K.K. and Bell,D.A. (2000) XPD polymorphisms: effects on DNA epair proficiency. Carcinogenesis, 21, 551–555.
31) MacKintosh ML, Rahim R, Rajashanker B, et al. CT scan does not predict optimal debulking in stage III–IV epithelial ovarian cancer: a multicentre validation study. J Obstet Gynaecol. 2014;34(5):424-8.
32) Mallen A, Todd S, Robertson SE, Kim J, Sehovic M, Wenham RM, Extermann M, Chon HS. Impact of age, comorbidity, and treatment characteristics on survival in older women with advanced high grade epithelial ovarian cancer. Gynecol Oncol. 2021 Jun;161(3):693-699.
33) Marchbanks PA, Wilson H, Bastos E, Cramer DW, Schildkraut JM, Peterson HB. Cigarette smoking and epithelial ovarian cancer by histologic type. Obstet Gynecol. 2018;95 (2):255–260.
34) Mathew, C. G. P. The isolation of high molecular weight eukaryotic DNA /C. G. P. Mathew //Nucleic Acids. – 1984 – P. 31-34.
35) Mavaddat N, Peock S, Frost D, et al. Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. J Natl Cancer Inst 2018;105 (11): 812-22.
36) Mitrunen K, Hirvonen A: Molecular epidemiology of sporadic breast cancer. The role of polymorphic genes involved in oestrogen biosynthesis and metabolism. Mutat Res. 544: 9-41. 10.1016.
37) Mori M, Harabuchi I, Miyake H, Casagrande JT, Henderson BE, Ross RK. Reproductive, genetic, and dietary risk factors for ovarian cancer. Am J Epidemiol. 2017;128(4):771–777.Kim SJ, Rosen B, Fan I, et al. Epidemiologic factors that predict long-term survival following a diagnosis of epithelial ovarian cancer. Br J Cancer. 2017;116(7):964.
38) Ness RB, Grisso JA, Cottreau C, et al. Factors related to inflammation of the ovarian epithelium and risk of ovarian cancer. Epidemiology. 2017;11(2):111–117.
39) Ong J-S, Cuellar-Partida G, Lu Y, et al. Association of vitamin D levels and risk of ovarian cancer: a Mendelian randomization study. Int J Epidemiol. 2017;45(5):1619–1630.
40) Orskov M, Iachina M, Guldberg R, Mogensen O, Norgard BM.Predictors of mortality within 1 year after primary ovarian cancersurgery: a nationwide cohort study. BMJ Open. 2016; 6.
41) Pavone ME, Lyttle BM. Endometriosis and ovarian cancer: links, risks, and challenges faced. Int J Womens Health. 2018;7:663.
42) Piver MS, Jishi MF, Tsukada Y, et al. Primary peritoneal carcinoma after prophylactic oophorectomy in women with a family history of ovarian cancer. A report of the Gilda Radner Familial Ovarian Cancer Registry. Cancer 199371 (9): 2751-5.
43) Prat Jaime and FIGO Committee on Gynecologic Oncology FIGO’s staging classification for cancer of the ovary, fallopian tube, and peritoneum: abridged republication.JGynecol Oncol. 2015;26(2):87-9.
44) Qiao,Y., Spitz,M.R., Shen,H., Guo,Z., Shete,S., Hedayati,M., Grossman,L., Mohrenweiser,H. and Wei,Q. (2002) Modulation of repair of ultraviolet damage in the host-cell reactivation assay by polymorphic XPC and XPD/ERCC2 genotypes. Carcinogenesis, 23, 295–299.
45) Reardon J.T., Sancar A. Thermodynamic cooperativity and kinetic proofreading in DNA damage recognition and repair. // Cell Cycle. — № 3. — P. 141—144.
46) Reigstad MM, Storeng R, Myklebust TA, et al. Cancer risk in women treated with fertility drugs according to parity status—A registry-based cohort study. Cancer Epidemiol Biomarkers Prev. 2017;26(6):953–962
47) Risch HA, Marrett LD, Jain M, Howe GR. Differences in risk factors for epithelial ovarian cancer by histologic type: results of a case-control study. Am J Epidemiol. 2017;144(4):363–372
48) Rodriguez C, Calle EE, Fakhrabadi-Shokoohi D, Jacobs EJ, Thun MJ. Body mass index, height, and the risk of ovarian cancer mortality in a prospective cohort of postmenopausal women. Cancer Epidemiol Biomarkers Prev. 2018;11 (9):822–828.
49) Rossing MA, Cushing-Haugen KL, Wicklund KG, Doherty JA, Weiss NS. Risk of epithelial ovarian cancer in relation to benign ovarian conditions and ovarian surgery. Cancer Causes Control. 2017;19(10):1357.
50) Sancar A. Mechanisms of DNA excision repair. // Science. — № 266
51) Shen,M.R., Jones,I.M. and Mohrenweiser,H. Nonconservative amino acid substitution variants exist at polymorphic frequency in DNA repair genes in healthy humans. Cancer Res., 58, 604–608.
52) Shushan A, Paltiel O, Iscovich J, Elchalal U, Peretz T, Schenker JG. Human menopausal gonadotropin and the risk of epithelial ovarian cancer. Fertil Steril. 2017;65(1):13–18.
53) Sieh W, Salvador S, McGuire V, et al. Tubal ligation and risk of ovarian cancer subtypes: a pooled analysis of case-control studies. Int J Epidemiol. 2018;42(2):579–589.
54) Sieh W, Salvador S, McGuire V, et al. Tubal ligation and risk of ovarian cancer subtypes: a pooled analysis of case-control studies. Int J Epidemiol. 2018;42(2):579–589.
55) Spitz,M.R., Wu,X., Wang,Y., Wang,L.E., Shete,S., Amos,C.I., Guo,Z., Lei,L., Mohrenweiser,H. and Wei,Q. (2001) Modulation of nucleotide excision repair capacity by XPD polymorphisms in lung cancer patients. Cancer Res., 61, 1354–1357
56) Wilkinson N. Pathology of the Ovary, Fallopian Tube and Peritoneum. London: Sprienger-Verlag; 2019.
57) Xiao S., Cui S., Lu X., Guan Y., Li D., Liu Q., Cai Y., Jin C., Yang J., Wu S., van der Straaten T. The ERCC2/XPD Lys751Gln poly-morphism affects DNA repair of benzo[a]pyrene induced damage, tested in an in vitro model. Toxicol. In Vitro. 2016; 34: 300-8.
58) Yang H, Dai H, Li L, Wang X, Wang P, Song F, Zhang B, Chen K.Age at menarche and epithelial ovarian cancer risk: A meta-analysis and Mendelian randomization study. Cancer Med. 2019 Jul; 8(8):4012-4022.
59) Yoshida K and Miki Y. Role of BRCA1 and BRCA2 as regulators of DNA repair, transcription, and cell cycle in response to DNA damage.Cancer Science 2017;95 (11): 866-871

Интернет-источники
60) GLOBOCAN 2020. https://gco.iarc.fr/today/online-analysis-pie?v=2020&mode=cancer&mode_population=continents&population=900&populations=900&key=total&sex=2&cancer=39&type=0&statistic=5&prevalence=0&population_group=0&ages;_group%5B%5D=0&ages;_group%5B%5D=17&nb_items=7&group_cancer=1&include_nmsc=1&include_nmsc_other=1&half_pie=0&donut=0
61) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6500433/?report=reader#!po=13.7500.
62) Yoshida K and Miki Y. Role of BRCA1 and BRCA2 as regulators of DNA repair, transcription, and cell cycle in response to DNA damage.Cancer Science2017;95 (11): 866-871.